2020 American Transplant Congress
Real-World Experiences in the Transplantation of Hepatitis C Positive Kidneys
*Purpose: With advancements of direct-acting antivirals, transplantation of HCV-NAT+ (HCV+) organs to HCV-negative (HCV-) recipients has been used to decrease wait times without apparent sacrifice…2020 American Transplant Congress
Viral Kinetics of De Novo HCV Infection and Response to Antiviral Therapy in Liver and Kidney Transplant Recipients Receiving HCV-Viremic Donors
*Purpose: There is general agreement that expanded use of organs from HCV-viremic donors is desirable, including in recipients without HCV infection. However, the optimal treatment…2020 American Transplant Congress
The Importance of Caveolin-1 Immunohistochemical Staining for BK Nephropathy Seen after Kidney Transplantation
*Purpose: To understand the importance of molecular expression of Caveolin-1 in BKV nephropathy seen after kidney transplantion.*Methods: The kidney transplant patients who had a graft…2020 American Transplant Congress
Incidence of Cytomegalovirus Infection in Deceased Donor Kidney Transplantation from Hepatitis-C Antibody Positive Donors to Hepatitis-C Antibody Negative Recipients: A National Registry Analysis
*Purpose: Deceased donor kidney transplantation (KT) from hepatitis C (HCV) infected donors into HCV uninfected recipients (HCV D+/R-) will be the standard of care in…2020 American Transplant Congress
Outcome after Kidney Transplantation in Hepatitis Surface Antigen-Positive Patients
Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: Because of the low prevalence of Hepatitis Surface Antigen (HBsAg)-positive patients, only a few reports have evaluated the actual outcome of these patients after…2020 American Transplant Congress
Temporal Trends in the Incidence and Impact of Infections Following Kidney Transplantation
Johns Hopkins University, Baltimore, MD
*Purpose: Infections remain a major threat to successful kidney transplantation (KT), and are associated with a subsequent higher risk of mortality and graft loss. However,…2020 American Transplant Congress
Immune Checkpoint Inhibitor Use in Kidney Transplant Recipients: Rejection Risk, Prevention and Transcriptional Signature in Allograft
1Brigham and Women's Hospital, Boston, MA, 2University of Alberta, Edmonton, AB, Canada
*Purpose: Immune checkpoint inhibitor (ICI) use has changed the landscape of cancer treatment. Several cases of acute rejection in use of ICI have been reported,…2020 American Transplant Congress
Treatment of BK Viremia in Kidney Transplant Recipients: A Single-Center Experience
Rush University Medical Center, Chicago, IL
*Purpose: Over the past 10 years, our center has utilized various strategies in managing BK viremia in our kidney transplant recipients. Reducing immunosuppression (IMS) in…2020 American Transplant Congress
Contrary to Expectation, the Use of Immune Checkpoint Inhibitors is Not Consistently Associated with Early Onset Allograft Rejection in Solid Organ Transplant Recipients
*Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are generally avoided in solid organ transplant recipients (SOTRs) due to concern for allograft rejection…2020 American Transplant Congress
Comparative Analysis of Risk Factors and Outcomes in Kidney Transplant Recipients with Lung Cancer and Those with No Malignancy: UNOS Data Set
*Purpose: Transplant recipients are at increased risk for malignancy. Patients who develop cancer after transplant have worse outcomes, especially those with lung cancer. Transplant-related risk…
- « Previous Page
- 1
- …
- 361
- 362
- 363
- 364
- 365
- …
- 1683
- Next Page »